The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.
 
Morihito Okada
Speakers' Bureau - Chugai Pharma; Covidien; Johnson & Johnson; Lilly; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Pfizer (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kentaro Tanaka
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan
Consulting or Advisory Role - Chugai Pharma
 
Hajime Asahina
No Relationships to Disclose
 
Taishi Harada
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kosuke Hamai
No Relationships to Disclose
 
Kana Watanabe
No Relationships to Disclose
 
Kunihiko Kobayashi
Consulting or Advisory Role - AstraZeneca Japan
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Kenji Sugio
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst)
 
Satoshi Oizumi
Honoraria - Chugai Pharma; Lilly Japan
Research Funding - Bristol-Myers Squibb Japan (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)